Results 121 to 130 of about 62,498 (301)

Chronic pain treatment experiences and barriers among opioid agonist treatment participants who inject drugs: A qualitative study

Addiction, EarlyView.
Abstract Background and aim Co‐occurring chronic pain affects nearly half of people receiving opioid use disorder (OUD) treatment. Although this pain is often severe, it is usually inadequately managed. Stigma and clinical complexity associated with OUD are thought to further restrict access to pain care.
Jie Yang, Shelley Walker, Amy G. McNeilage, Peter Higgs, Louisa Picco, Paul Dietze, Suzanne Nielsen   +6 more
wiley   +1 more source

Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl

Addiction Science & Clinical Practice
Background In response to greater illicit fentanyl use, buprenorphine daily doses exceeding the FDA’s recommended target daily dose (16 mg) and maximum suggested daily dose (24 mg) may provide better outcomes, but little is known about higher dosage ...
Bradley D. Stein, Flora Sheng, Brendan K. Saloner, Adam J. Gordon, Jessica S. Merlin   +4 more
doaj   +1 more source

Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids

, 2015
Jon Andsnes Berg,1 Jan Schjøtt,1,2 Kjell O Fossan,1 Bettina Riedel1,21Section of Clinical Pharmacology, Laboratory of Clinical Biochemistry, Haukeland University Hospital, 2Faculty of Medicine and Dentistry, Department of Clinical Science ...
Fossan KO, Schjøtt J, Berg JA, Riedel B   +3 more
core  

Buprenorphine and the Opioid Crisis: A Primer for Congress [PDF]

, 2018
This report addresses questions policymakers may have about the effectiveness of the opioid addiction treatment drug buprenorphine, the demand for buprenorphine, and access to ...
Duff, Johnathan H.
core  

Variation in 90‐day substance use disorder‐related acute care events across United States opioid treatment programs: A Medicaid claims analysis

Addiction, EarlyView.
Abstract Background and aims Creating and tracking quality measures has improved outcomes in many areas of healthcare; however, quality measures specific to opioid treatment programs (OTPs) have not yet been developed. Based on the success seen in other fields, introducing quality measures in OTPs should help enhance positive outcomes and decrease ...
Barrett Wallace Montgomery, Tami L. Mark, Thanh Lu, William N. Dowd, Dylan DeLisle, Kathryn N. Burke, Daniel H. Barch, Gary A. Zarkin   +7 more
wiley   +1 more source

Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM)

, 2018
Ane Erdal,1 Elisabeth Flo,2 Dag Aarsland,3,4 Geir Selbaek,5–7 Clive Ballard,8 Dagrun D Slettebo,1 Bettina S Husebo1,9 1Department of Global Public Health and Primary Care, Centre for Elderly and Nursing Home Medicine, University of Bergen, Bergen,
Flo E, Husebo BS, Slettebo DD, Erdal A, Ballard C, Aarsland D, Selbaek G   +6 more
core  

Availability of Buprenorphine Treatment in Kentucky [PDF]

, 2016
Drug overdose and substance use treatment admissions data indicate that opioid use is problematic in Kentucky, but little information exists about the geographic availability of buprenorphine treatment across the state.
Borders, Tyrone F., Myers, Elijah T.
core  

Heroin overdose risk profiles following long‐term heroin dependence: Findings from the 18‐ to 20‐year follow‐up of the Australian treatment outcome study

Addiction, EarlyView.
Abstract Aims To identify heroin overdose and polydrug risk profiles of Australian adults with long‐term heroin dependence and assess if psychosocial, treatment, physical and mental health‐related covariates were associated with class membership. Design The 18–20‐year follow‐up of the Australian Treatment Outcome Study (ATOS). Setting Sydney, New South
Jessy S. Lim, Christina Marel, Tim Slade, Jack Wilson, Maree Teesson, Paul S. Haber, Katherine L. Mills   +6 more
wiley   +1 more source

Buprenorphine initiation from fentanyl using low-dose intramuscular ketamine: a pilot study

Addiction Science & Clinical Practice
Background Buprenorphine is an effective medication for treating opioid use disorder but is underutilized partly due to patient apprehensiveness of the severe withdrawal symptoms it can induce when started, particularly by fentanyl-dependent individuals.
J. Luke Engeriser, Thomas Hutch, Crystal L. Smith, Zach Orme, Evan Chavers, Lucinda A. Grande   +5 more
doaj   +1 more source

Norbuprenorphine and respiratory depression: Exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine

, 2018
Objectives: To investigate plasma levels of buprenorphine and norbuprenorphine and their relationship to respiratory depression. Materials and methods: Opioid-dependent subjects were randomized 2: 1 to novel lyophilized rapid-disintegrating tablet (“bup ...
James Bell, Baillie, Shelagh, Alastair Knight, Reed, Kylie, Karolina Bogdanowicz, Kylie Reed, Bell, James, Bogdanowicz, Karolina, John Strang, Knight, Alastair, Shelagh Baillie, Strang, John; id_orcid   +11 more
core   +1 more source